Every 10-Q that Dyne Therapeutics, Inc. (DYN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DYN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DYN filings page.
Dyne Therapeutics is a clinical-stage neuromuscular company with no product revenue and a growing investment in late-stage programs. For the six months ended June 30, 2026, it recorded a net loss of $299.4 million, up from $226.2 million, driven by higher R&D of $253.2 million and G&A of $53.8 million, reflecting expanded manufacturing, pivotal trials and headcount.
Liquidity remains strong: at June 30, 2026 the company held $676.1 million in cash and cash equivalents, $222.4 million in marketable securities and $2.4 million in restricted cash. Long-term debt under a Hercules term loan totaled $200.0 million in principal (11.6% effective rate in the quarter), alongside a $14.2 million vendor financing balance, and stockholders’ equity was $702.2 million. A July 2026 follow-on equity offering added about $405.0 million of net proceeds, and management expects existing resources to fund operations, debt service and capital needs into the second quarter of 2028.
The lead DMD candidate z-rostudirsen has a biologics license application accepted with FDA priority review and a PDUFA action date of January 21, 2027; the confirmatory Phase 3 FORZETTO trial is underway. DM1 candidate z-basivarsen is in a registrational Phase 1/2 ACHIEVE cohort and Phase 3 HARMONIA; the expansion cohort is fully enrolled, with data intended to support a 2027 BLA and a potential U.S. launch in the first half of 2028. FSHD candidate DYNE-302 received IND clearance to start Phase 1, while Pompe candidate DYNE-401 and tau-targeting CNS conjugates remain in preclinical development.
Dyne Therapeutics reported a net loss of $120.9 million for the quarter ended March 31, 2026, slightly higher than the $115.4 million loss a year earlier, as it continues to advance multiple neuromuscular programs.
Research and development expenses were $100.9 million, reflecting manufacturing and clinical work on z-rostudirsen for Duchenne muscular dystrophy and z-basivarsen for myotonic dystrophy type 1, plus preclinical efforts in FSHD and Pompe. General and administrative costs rose to $24.4 million as Dyne scales commercial and corporate infrastructure. The company ended the quarter with $972.2 million in cash, cash equivalents and marketable securities and a term loan balance of $150.0 million, and believes this liquidity will fund operations, debt service and capital needs into the first quarter of 2028 while it targets potential first product launches beginning in 2027.
Dyne Therapeutics (DYN) filed its Q3 2025 10‑Q, reporting higher cash and continued R&D investment. Cash and cash equivalents were $573.6 million, with marketable securities of $218.3 million. Total assets reached $867.1 million. The company posted a Q3 net loss of $108.0 million ($0.76 per share) on operating expenses of $113.9 million, driven by research and development of $97.2 million and general and administrative of $16.7 million.
To strengthen liquidity, Dyne completed a public offering for net proceeds of $215.8 million and sold $140.6 million via its at‑the‑market program year‑to‑date. It also drew $100.0 million under a term loan with Hercules, due July 1, 2030, bearing interest at the prime rate (floor 7.50%) plus 2.45%. Long‑term debt, net, was $99.1 million. Shares outstanding were 142.6 million at quarter‑end.
Program updates include FDA Breakthrough Therapy Designation for z‑basivarsen (DM1) and initiation of a registrational expansion cohort in ACHIEVE. For z‑rostudirsen (DMD), the DELIVER 20 mg/kg Q4W registrational expansion cohort completed enrollment, with data planned in December 2025. Subsequent to quarter‑end, Dyne committed at least $25.5 million through March 2027 under a CMO manufacturing agreement.